LXRX
NASDAQLexicon Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Website
News25/Ratings5
News · 26 weeks65-94%
2025-10-262026-04-19
Mix4690d
- Insider23(50%)
- SEC Filings13(28%)
- Other5(11%)
- Offering3(7%)
- Earnings2(4%)
Latest news
25 items- PRLexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingOral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further validates the broader potential importance of the AAK1 pathway in neurologic diseases THE WOODLANDS, Texas, April 17, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) supporting the selection of pilavapadin 10 mg as the optimal dose for Phase 3 development will be presented on Wednesday April 22, during the American Academy of Neurology (AAN) Annual
- PRLexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & ExpoTHE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced three presentations of sotagliflozin clinical data during the American College of Cardiology (ACC) Annual Meeting. The congress is being held March 28-30 in New Orleans, Louisiana. Lexicon will present data from the Phase 3 SCORED study of sotagliflozin in people with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. In a prespecified analysis, patients were stratified by baseline body mass index (BMI), and the results demonstrated that sotagliflozin reduced heart failure and major adverse cardiovascular events (MACE) irrespective of BMI. Prese
- SECSEC Form DEFA14A filed by Lexicon Pharmaceuticals Inc.DEFA14A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- SECSEC Form DEF 14A filed by Lexicon Pharmaceuticals Inc.DEF 14A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- PRLexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for DiabetesTHE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The congress is being held March 11-14, 2026, in Barcelona, Spain. "Recognizing that a patient's kidney function can impact the efficacy of SGLT inhibitors, we conducted this post hoc analysis of clinical data from two identically-des
- SECSEC Form 10-K filed by Lexicon Pharmaceuticals Inc.10-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- SECLexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- PRLexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical UpdatesPivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments. "
- PRChronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightThe chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor
- PRLexicon Pharmaceuticals to Participate in Three Upcoming March Investor ConferencesTHE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m. Lexicon will also be participating in 1x1 investor meetings at the 2026 Jefferies Biotech on the Beach Summit, March 10–11, and at the Barclays 28th Global Healthcare Conference, March 10-12. A live recording and replay of the Leerink fireside chat can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharma
- INSIDERSVP, Human Resources Mcdermott Wendy converted options into 224,406 shares and covered exercise/tax liability with 68,107 shares, increasing direct ownership by 128% to 277,945 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSVP, Partnerships & Corp Strat Martens Rachel Yap converted options into 67,090 shares and covered exercise/tax liability with 35,826 shares (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSVP, Chief Medical Officer Granowitz Craig B converted options into 312,276 shares and covered exercise/tax liability with 109,098 shares, increasing direct ownership by 169% to 323,430 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSVP, Discovery Gopinathan Suma converted options into 99,950 shares and covered exercise/tax liability with 24,338 shares, increasing direct ownership by 101% to 150,132 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSVP, IR and Corp Comm Defrancesco Lisa converted options into 152,864 shares and covered exercise/tax liability with 74,572 shares, increasing direct ownership by 503% to 93,869 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSVP, General Counsel & Secr. Crum Brian T converted options into 273,006 shares and covered exercise/tax liability with 105,019 shares, increasing direct ownership by 30% to 428,802 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSVP, Chief Financial Officer Coiante Scott M covered exercise/tax liability with 54,881 shares and converted options into 160,237 shares (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERChief Executive Officer Exton Michael covered exercise/tax liability with 204,831 shares and converted options into 503,263 shares (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- PRLexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast w
- INSIDERDirector Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Debbane Raymond bought $219,755 worth of shares (150,000 units at $1.47), increasing direct ownership by 9% to 1,804,186 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Artal Participations S.A R.L. was granted 41,290 units of Series B Convertible Preferred Stock (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Debbane Raymond bought $352,889 worth of shares (268,497 units at $1.31), increasing direct ownership by 19% to 1,654,186 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- SECSEC Form PRE 14A filed by Lexicon Pharmaceuticals Inc.PRE 14A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)